Alnylam Pharmaceuticals, Inc. (ALNY) Earnings

Alnylam Pharmaceuticals, Inc.

ALNY · NASDAQ-GS

Sep 2026upcoming

Next quarter

Consensus is $1.70 EPS for Sep 2026 across 9 estimates, ranging $1.27 to $2.87.

ALNY Jun 2026

Reported Jul 30, 2026

Miss 15.97%

EPS estimate: $1.44
EPS actual: $1.21
Revenue estimate: —
Revenue actual: —
1-day move: +0.02%

Call highlights have not been generated for this quarter.

Symbol: ALNY
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NASDAQ-GS

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.

Key Issues

Bullish view

AMVUTTRA continued to gain traction, driving approximately $1.2 billion of second-quarter global net product revenue and 74% year-over-year growth. Strong uptake could eventually outweigh the reduced full-year TTR sales outlook.

Bearish view

Management’s 2026 TTR product-sales guidance reduction indicates that near-term demand or execution is weaker than investors expected. The guidance cut dominated the quarter despite record AMVUTTRA sales.

Analyst Consensus

See all

Buy

26 analysts

$228

Current

$357

Low

$375

Average

$357

High

Average target implies +64.45% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Biogen Inc.BIIB · NASDAQ-GS$208.21